WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 412413
CAS#: 610309-89-2
Description: Carvedilol phosphate has alpha as well as beta blocking activity.
MedKoo Cat#: 412413
Name: Carvedilol phosphate
CAS#: 610309-89-2
Chemical Formula: C48H60N4O17P2
Exact Mass: 1026.3429
Molecular Weight: 1026.97
Elemental Analysis: C, 56.14; H, 5.89; N, 5.46; O, 26.48; P, 6.03
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Carvedilol phosphate; Coreg CR; SKF105517D; SKF-105517D; SKF 105517D
IUPAC/Chemical Name: bis(1-((9H-carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol) bis(phosphate) hydrate
InChi Key: LHNYXTULDSJZRB-UHFFFAOYSA-N
InChi Code: InChI=1S/2C24H26N2O4.2H3O4P.H2O/c2*1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;2*1-5(2,3)4;/h2*2-12,17,25-27H,13-16H2,1H3;2*(H3,1,2,3,4);1H2
SMILES Code: COc1c(OCCNCC(COc(ccc2)c3c2[nH]c4c3cccc4)O)cccc1.COc5c(OCCNCC(COc(ccc6)c7c6[nH]c8c7cccc8)O)cccc5.OP(O)(O)=O.OP(O)(O)=O.O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 1026.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Polonini H, da Silva SL, Brandão MAF, Bauters T, De Moerloose B, Ferreira AO. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4. Int J Pharm Compd. 2018 Nov-Dec;22(6):516-526. PMID: 30384353.
2: Allada R, Maruthapillai A, Palanisamy K, Chappa P. Moisture Sorption- desorption Characteristics and the Corresponding Thermodynamic Properties of Carvedilol Phosphate. J Pharm Bioallied Sci. 2017 Jan-Mar;9(1):16-21. doi: 10.4103/0975-7406.206216. PMID: 28584488; PMCID: PMC5450465.
3: Okumura K, Kato H, Honjo O, Breitling S, Kuebler WM, Sun M, Friedberg MK. Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. J Mol Med (Berl). 2015 Jun;93(6):663-74. doi: 10.1007/s00109-015-1251-9. Epub 2015 Jan 18. PMID: 25595602.
4: Oliveira PJ, Esteves T, Rolo AP, Palmeira CM, Moreno AJ. Carvedilol inhibits the mitochondrial permeability transition by an antioxidant mechanism. Cardiovasc Toxicol. 2004;4(1):11-20. doi: 10.1385/ct:4:1:11. PMID: 15034201.
5: Avachat AM, Patel KB, Rokade MS, Dash RR. Formulation and characterization of an expandable, gastroretentive system of carvedilol phosphate by 32 factorial design. PDA J Pharm Sci Technol. 2011 Jan-Feb;65(1):12-9. PMID: 21414936.
6: Yilmaz B, Arslan S. HPLC/Fluorometric Detection of Carvedilol in Real Human Plasma Samples Using Liquid-Liquid Extraction. J Chromatogr Sci. 2016 Mar;54(3):413-8. doi: 10.1093/chromsci/bmv157. Epub 2015 Nov 3. PMID: 26538492.
7: Yeh CH, Chen TP, Wang YC, Lin YM, Fang SW. Carvedilol treatment after myocardial infarct decreases cardiomyocytic apoptosis in the peri-infarct zone during cardioplegia-induced cardiac arrest. Shock. 2013 Apr;39(4):343-52. doi: 10.1097/SHK.0b013e31828c588a. PMID: 23481492.
8: Srikanth Meka V, Wee Liang VA, Dharmalingham SR, Sheshala R, Gorajana A. Preparation and in vitro characterization of non-effervescent floating drug delivery system of poorly soluble drug, carvedilol phosphate. Acta Pharm. 2014 Dec;64(4):485-94. doi: 10.2478/acph-2014-0038. PMID: 25531788.
9: Hashemzadeh M, Movahed MR, Russu WA, Soroush L, Hill DN. Novel design and synthesis of modified structure of carvedilol. Recent Pat Cardiovasc Drug Discov. 2011 Sep;6(3):175-9. doi: 10.2174/157489011797376988. PMID: 21834769.
10: Chakraborty S, Shukla D, Jain A, Mishra B, Singh S. Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J Colloid Interface Sci. 2009 Jul 15;335(2):242-9. doi: 10.1016/j.jcis.2009.03.047. Epub 2009 Apr 5. PMID: 19403142.
